Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
A

Ratings ESG MSCI

Ratings Jazz Pharmaceuticals plc: Strengths and Weaknesses

Highlights: Jazz Pharmaceuticals plc
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses: Jazz Pharmaceuticals plc
  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.

Rating Financials

Jazz Pharmaceuticals plc SectorUnited States
Fundamentals
Growth
Revenue growth
EPS growth
FCF growth
Profitability
EBITDA Margin
EBIT Margin
Net Margin
Capital Efficiency
ROA
ROCE
ROE
Financial Health
Gearing
Leverage
Capital Intensity
Balance sheet growth
Long Term balance sheet growth-
Long term revenue growth
Long term EPS growth
More ratings

Rating Valuation

Jazz Pharmaceuticals plc SectorUnited States
Global Valuation
Enterprise value
EV/Revenue
EV/EBITDA
EV/FCF
Equity Valuation
P/E
PBR
Dividend Yield-
EV/EBIT
CAPEX/Revenue
More ratings

Rating Consensus

Jazz Pharmaceuticals plc SectorUnited States
Consensus
Analysts' buy/sell recommendations
Analysts' recommendations evolution (1 year)
Analysts' recommendations evolution (4 months)
Analysts' target price
Analysts' target price evolution (1 year)
Analysts' target price evolution (4 months)
Analysts' recommendations evolution (7 days)
Target Price evolution (7 days)
More ratings

Rating Business Predictability

Jazz Pharmaceuticals plc SectorUnited States
Visibility
Analysts' coverage
Financial estimates divergence
Analysts' recommendations divergence
Analysts' Target price divergence
Surprise rates

Rating Revisions

Jazz Pharmaceuticals plc SectorUnited States
Financial revisions
Revenue revisions (1 year)
Revenue revisions (4 months)
EPS revisions (1 year)
EPS revisions (4 months)
EPS revisions (7 days)
Revenue revisions (7 days)
More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
10.02B
A
904B
A
506B
BBB
396B
AA
342B
AA
283B
A
256B
AAA
246B
A
223B
A
171B
A
Average 333.7B
AA
Weighted average by Cap.
AA
See all sector ratings
  1. Stock Market
  2. Equities
  3. JAZZ Stock
  4. Ratings Jazz Pharmaceuticals plc